Solving Kids Cancer Inc

Organization Overview

Solving Kids Cancer Inc is located in New York, NY. The organization was established in 2007. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. As of 12/2021, Solving Kids Cancer Inc employed 5 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Solving Kids Cancer Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 12/2021, Solving Kids Cancer Inc generated $676.7k in total revenue. The organization has seen a slow decline revenue. Over the past 7 years, revenues have fallen by an average of (1.2%) each year. All expenses for the organization totaled $1.2m during the year ending 12/2021. As we would expect to see with falling revenues, expenses have declined by (1.5%) per year over the past 7 years. You can explore the organizations financials more deeply in the financial statements section below.

Since 2015, Solving Kids Cancer Inc has awarded 24 individual grants totaling $3,116,886. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.

Mission & Program ActivityExcerpts From the 990 Filing

TAX YEAR

2021

Describe the Organization's Mission:

Part 3 - Line 1

MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS USING A PATIENT-CENTRIC APPROACH OF DRIVING/SUPPORTING HIGH-IMPACT CLINICAL RESEARCH, PRECLINICAL THERAPEUTIC DEVELOPMENT PROJECTS, CONDUCTING RESEARCH ADVOCACY IN THE LANDSCAPE AND EMPOWERING FAMILIES WITH RESOURCES/TOOLS TO HELP THEM NAVIGATE TREATMENT OPTIONS FOR THEIR CHILD.

Describe the Organization's Program Activity:

Part 3 - Line 4a

SKC AND OUR ADVISORS SURVEY, DISCUSS AND PRIORITIZE THE GREATEST UNMET NEEDS WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP PROGRAMS TO ADDRESS THEM. (1) SKC TARGETS ONLY THE MOST CHALLENGING AND POOREST OUTCOME CHILDHOOD CANCERS THAT REQUIRE SIGNIFICANT HELP AND HAVE THE GREATEST UNMET NEED INCLUDING HIGH-RISK BRAIN TUMORS AND SOLID TUMORS. (2) TAKES A GLOBAL APPROACH TO SUPPORTING PROGRAMS TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (3) PRIORITIZES ADVANCING TREATMENT OPTIONS THAT HAVE THE HIGHEST POTENTIAL FOR CURATIVE RESPONSES RATHER THAN PARTIAL TUMOR SHRINKAGE OR TEMPORARY LIFE EXTENSION. (4) TAKES LEADERSHIP ROLES WITHIN INFLUENTIAL NATIONAL AND INTERNATIONAL RESEARCH GROUPS' ADVISORY BOARDS AND CO-AUTHOR INFLUENTIAL PAPERS IN PROFESSIONAL JOURNALS TO DRIVE NEW DIRECTION TO POSITIVELY IMPACT PATIENTS. (5) IMPLEMENTS ADVOCACY AND ACTIVISM TO ENSURE THAT THE PATIENTS VOICE AND NEEDS ARE FRONT-AND-CENTER IN THE RESEARCH COMMUNITY'S AGENDAS AND PLANS. (6) DIRECTS RESEARCH FUNDING AND PROGRAMS TO THE FRONTLINES OF IMPACTING PEDIATRIC CLINICAL TRIALS AND DEVELOPING NEW TREATMENTS. (7) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE.SURVIVAL RATES REMAIN UNSATISFACTORILY LOW FOR THE DEADLIEST CHILDHOOD CANCERS WHILE DECADES-OLD MODALITIES LIKE CHEMOTHERAPY AND RADIATION REMAIN THE PROMINENT STANDARDS-OF-CARE AND ARE NOT CURATIVE FOR NEARLY HALF OF HIGH-RISK PATIENTS. SKC FOCUSES ON ADVANCING NOVEL AGENTS/COMBINATIONS WITH THE HIGHEST CURATIVE RATIONALE WITHIN ALL PARTS OF THE TREATMENT CONTINUUM, STARTING IN CHILDREN WITH RELAPSE/REFRACTORY DISEASE, WITH A GOAL TO MOVE NEW TREATMENTS INTO FRONTLINE TREATMENT REGIMENS FOR NEWLY DIAGNOSED CHILDREN ESTABLISHING A GOLD STANDARD-OF-CARE IN A PERSONALIZED APPROACH PROVIDING THE RIGHT TREATMENTS TO THE RIGHT PATIENTS AT THE RIGHT TIME. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY (VACCINES, CELLULAR THERAPY, ONCOLYTIC VIROTHERAPY, THERAPEUTIC ANTIBODIES, CHECKPOINT INHIBITORS), SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. SKC HAS SUPPORTED 28 CLINICAL TRIALS RESULTING IN 25 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH HIGH-RISK CANCERS AND 16 PRECLINICAL DEVELOPMENT PROJECTS.OUR MOST RECENT PROGRAMS INCLUDE A NEW FRONTLINE CLINICAL TRIAL FOR HIGH RISK NEUROBLASTOMA INCORPORATING A GENOMICALLY TARGETED THERAPEUTIC IN COMBINATION WITH STANDARD-OF-CARE IN A MULTI-INSTITUTIONAL, GLOBAL TRIAL; A GLOBAL, MULTI-CENTER CLINICAL TRIAL FOR HIGH-RISK NEUROBLASTOMA USING A TRIPLET COMBINATION OF IMMUNOTHERAPY AND TARGETED RADIOTHERAPY FOR CHILDREN WHO RELAPSE; A MULTI-CENTER COLLABORATIVE PROGRAM TO DEVELOP A NEW PROGNOSTIC BIOMARKER SIGNATURE (ULTRA HIGH RISK) FOR NEUROBLASTOMA; A MULTI-CENTER PROGRAM TO DEVELOP A BIOMARKER SIGNATURE FOR INDOLENT (TREATMENT RESISTANT/REFRACTORY) TUMORS AND TEST A PIPELINE OF CANDIDATE COMBINATION THERAPIES, PROGNOSTIC BIOMARKER SIGNATURE (ULTRA HIGH RISK) FOR NEUROBLASTOMA; AND A NEW INITIATIVE FOR MEDULLOBLASTOMA TO IDENTIFY PROMISING COMBINATION THERAPIES THAT CROSS THE BLOOD-BRAIN BARRIER AS WELL AS NEW DELIVERY MECHANISMS.


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Board, Officers & Key Employees

Name (title)Compensation
Scott Kennedy
Executive Director, Co-Fou
$140,865
John London
Chairman, Co-Founder
$0
Channing Stave PHD
Secretary
$0
Eyal Soffer
Treasurer
$0
Hearn Jay Cho MD
Director
$0
Mark Savoye
Director
$0

Financial Statements

Statement of Revenue
Federated campaigns$0
Membership dues$0
Fundraising events$101,438
Related organizations$0
Government grants $76,960
All other contributions, gifts, grants, and similar amounts not included above$513,251
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$691,649
Total Program Service Revenue$0
Investment income $7,113
Tax Exempt Bond Proceeds $0
Royalties $0
Net Rental Income $0
Net Gain/Loss on Asset Sales $0
Net Income from Fundraising Events -$22,029
Net Income from Gaming Activities $0
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $676,733

Grants Awarded

Over the last fiscal year, Solving Kids Cancer Inc has awarded $307,831 in support to 3 organizations.

Grant RecipientAmount

CHILDREN'S HOSPITAL OF PHILADELPHIA

Org PageRecipient Profile

Philadelphia, PA

PURPOSE: CANCER RESEARCH

$236,075

CONQUER CANCER ASCO FOUNDATION

Org PageRecipient Profile

Alexandria, VA

PURPOSE: CANCER RESEARCH

$50,000

BOSTON CHILDREN'S HOSPITAL

Org PageRecipient Profile

Boston, MA

PURPOSE: CANCER RESEARCH

$21,756
View Grant Profile

Grants Recieved

Over the last fiscal year, we have identified 16 grants that Solving Kids Cancer Inc has recieved totaling $253,244.

Awarding OrganizationAmount
Band Of Parents Inc

New York, NY

PURPOSE: CHARITABLE

$85,000
Wades Army

Skillman, NJ

PURPOSE: CLINICAL RESEARCH

$50,000
Roux Family Foundation

Wellesley, MA

PURPOSE: GENERAL CHARITABLE CONTRIBUTION FOR HEALTHCARE

$25,000
Jewish Communal Fund

New York, NY

PURPOSE: GENERAL SUPPORT

$21,000
Feinberg Family Foundation

Greenwich, CT

PURPOSE: TO SUPPORT CANCERRESEARCH

$20,000
Childrens Neuroblastoma Cancer Foundation

Bloomingdale, IL

PURPOSE: RESEARCH

$20,000
View Grant Recipient Profile

Create an account to unlock the data you need.

or